531 related articles for article (PubMed ID: 33967228)
1. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.
Arrieta A; Galvis AE; Morphew T; Ehwerhemuepha L; Osborne S; Enriquez C; Imfeld K; Hoang J; Nieves D; Ashouri N; Singh J; Nugent D
Pediatr Infect Dis J; 2021 Jul; 40(7):606-611. PubMed ID: 33967228
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
[TBL] [Abstract][Full Text] [Related]
4. Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation.
Park H; Yu C; Pirofski LA; Yoon H; Wu D; Li Y; Tarpey T; Petkova E; Antman EM; Troxel AB;
BMC Infect Dis; 2024 Jun; 24(1):639. PubMed ID: 38926676
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
6. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
7. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional experience with COVID-19 convalescent plasma in children.
Jacquot C; Gordon O; Noland D; Donowitz JR; Levy E; Jain S; Willis Z; Rimland C; Loi M; Arrieta A; Annen K; Drapeau N; Osborne S; Ardura MI; Arora S; Zivick E; Delaney M
Transfusion; 2023 May; 63(5):918-924. PubMed ID: 36965173
[TBL] [Abstract][Full Text] [Related]
10. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
11. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
Herman JD; Wang C; Burke JS; Zur Y; Compere H; Kang J; Macvicar R; Taylor S; Shin S; Frank I; Siegel D; Tebas P; Choi GH; Shaw PA; Yoon H; Pirofski LA; Julg BD; Bar KJ; Lauffenburger D; Alter G
Cell Rep Med; 2022 Nov; 3(11):100811. PubMed ID: 36351430
[TBL] [Abstract][Full Text] [Related]
12. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19.
Inbar T; Dann EJ; Kerner O; Stern A
Transfusion; 2024 Mar; 64(3):443-448. PubMed ID: 38327238
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
Ortigoza MB; Yoon H; Goldfeld KS; Troxel AB; Daily JP; Wu Y; Li Y; Wu D; Cobb GF; Baptiste G; O'Keeffe M; Corpuz MO; Ostrosky-Zeichner L; Amin A; Zacharioudakis IM; Jayaweera DT; Wu Y; Philley JV; Devine MS; Desruisseaux MS; Santin AD; Anjan S; Mathew R; Patel B; Nigo M; Upadhyay R; Kupferman T; Dentino AN; Nanchal R; Merlo CA; Hager DN; Chandran K; Lai JR; Rivera J; Bikash CR; Lasso G; Hilbert TP; Paroder M; Asencio AA; Liu M; Petkova E; Bragat A; Shaker R; McPherson DD; Sacco RL; Keller MJ; Grudzen CR; Hochman JS; Pirofski LA; ; Parameswaran L; Corcoran AT; Rohatgi A; Wronska MW; Wu X; Srinivasan R; Deng FM; Filardo TD; Pendse J; Blaser SB; Whyte O; Gallagher JM; Thomas OE; Ramos D; Sturm-Reganato CL; Fong CC; Daus IM; Payoen AG; Chiofolo JT; Friedman MT; Wu DW; Jacobson JL; Schneider JG; Sarwar UN; Wang HE; Huebinger RM; Dronavalli G; Bai Y; Grimes CZ; Eldin KW; Umana VE; Martin JG; Heath TR; Bello FO; Ransford DL; Laurent-Rolle M; Shenoi SV; Akide-Ndunge OB; Thapa B; Peterson JL; Knauf K; Patel SU; Cheney LL; Tormey CA; Hendrickson JE
JAMA Intern Med; 2022 Feb; 182(2):115-126. PubMed ID: 34901997
[TBL] [Abstract][Full Text] [Related]
14. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A
N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609
[TBL] [Abstract][Full Text] [Related]
15. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
16. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 convalescent plasma.
Tobian AAR; Cohn CS; Shaz BH
Blood; 2022 Jul; 140(3):196-207. PubMed ID: 34695186
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
[TBL] [Abstract][Full Text] [Related]
20. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
